Literature DB >> 21372711

Is there still a role for reconstructive microsurgery in tubal infertility?

Cordula Schippert1, Guillermo-José Garcia-Rocha.   

Abstract

PURPOSE OF REVIEW: To review the current role of tubal reconstructive surgery in the era of assisted reproductive techniques (ARTs). RECENT
FINDINGS: After tubal reconstructive surgery, couples may have unlimited attempts to conceive naturally. Operative risks are low; the risk for ectopic pregnancy after surgery is 4-10%. ART is associated with a number of potential complications: severe ovarian hyperstimulation syndrome (0.25-2%), multiple pregnancies (up to 25%), a higher rate of major malformations and stillbirths, and ectopic pregnancy (1-13%). Birth rates following ART differ between 19 and 35%, depending on different laws governing the fertilization of a limited number of oocytes and the number of embryos transferred. Resterilization is a main indication for microsurgery with resulting pregnancy rates up to 84%. Salpingostomy and dense adhesiolysis have the lowest success rates (term pregnancy rates: 3-65%). Proximal tubal obstructions can be successfully treated by tubocornual anastomosis. Hydrosalpinges should be removed prior to in-vitro fertilization if they cannot be reconstructed. ART is recommended for patients older than 37-38 years, for women with severe tubal pathology, after repeated ectopic pregnancies, and in case of male infertility.
SUMMARY: Tubal reconstructive surgery still plays a role in infertility treatment. ART has not replaced microsurgery routinely as first-line treatment for tubal infertility.

Entities:  

Mesh:

Year:  2011        PMID: 21372711     DOI: 10.1097/GCO.0b013e328345522a

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  1 in total

1.  Effect comparison of salpingectomy versus proximal tubal occlusion on ovarian reserve: A meta-analysis.

Authors:  Shuxie Wu; Qiong Zhang; Yanping Li
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.